20-F: Inspira Technologies Reports Full Year 2024 Results, Highlights Regulatory Milestones and Strategic Collaborations

Inspira Technologies' 2024 annual report details progress in regulatory approvals, product development, and strategic partnerships, while also addressing financial challenges and future growth strategies.

Summary

• Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, released its annual report for the fiscal year ended December 31, 2024.
• The company is focused on developing life support technologies, aiming to replace traditional mechanical ventilators.
• Inspira's flagship product, the INSPIRA ART system, is designed to oxygenate blood and monitor blood parameters in real-time, potentially avoiding the need for invasive mechanical ventilation.
• The INSPIRA ART100 system received 510(k) clearance from the FDA in May 2024 and regulatory approval from the Israeli Medical Equipment Division (AMAR) in July 2024.
• First INSPIRA ART100 devices were shipped to Westchester Medical Center in December 2024 for evaluation and collaboration.
• The HYLA blood sensor, designed for real-time blood parameter analysis, is undergoing clinical evaluation with a 510(k) clearance submission targeted for the second half of 2025.
• The company reported net losses of approximately $11 million for 2024 and $11.3 million for 2023, with an accumulated deficit of approximately $67 million as of December 2024.
• The report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• As of December 31, 2024, the company's cash and cash equivalents, short-term deposits, and long-term deposits were approximately $5.8 million.
• The company expects to require additional capital to fund operations and commercialize its products.
• On March 10, 2025, Nasdaq notified Inspira Technologies that it was not in compliance with the minimum bid price requirement.
• The company is actively working to establish collaborations with strategic partners, leading hospitals, medical device companies, and distributors.
• Inspira is targeting intensive care units, general medical units, operating theaters, and small urban and rural hospitals to increase access to its solutions.
• The company is an Israeli corporation based in Raanana, Israel, and was incorporated in 2018.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in regulatory approvals and product development, the financial losses and going concern warning raise concerns. The Nasdaq non-compliance notice further contributes to a neutral to slightly negative outlook.

Positives

• FDA 510(k) clearance for the INSPIRA ART100 system.
• AMAR regulatory approval for the INSPIRA ART100 system.
• Clinical evaluation of the HYLA blood sensor is underway.
• Strategic collaborations with Westchester Medical Center and other leading hospitals.
• Development of the VORTX blood oxygenation delivery system with U.S. patent approval.
• Progress in developing single-use disposables for blood oxygenation procedures.
• Plans to develop the INSPIRA Cardi-ART for emergency response during cardiac arrest.
• ISO 13485:2016 Standard Certification received, indicating a robust quality management system.

Negatives

• Net losses of approximately $11 million for 2024 and $11.3 million for 2023.
• Accumulated deficit of approximately $67 million as of December 2024.
• Explanatory paragraph in the financial statements regarding substantial doubt about the company's ability to continue as a going concern.
• Nasdaq notification of non-compliance with the minimum bid price requirement on March 10, 2025.

Risks

• Dependence on successful development, marketing, and sale of products and receipt of required regulatory approvals.
• Limited operating history and significant operating losses since inception.
• Need to raise substantial additional funding, which may not be available on acceptable terms.
• Intense competition in the medical device industry.
• Potential product liability, warranty, or similar claims and product recalls.
• Impact of changes in general economic conditions and potential political, economic, and military instability in Israel.
• Risk of computer system failures, cyber-attacks, or a deficiency in cybersecurity.
• Dependence on third-party manufacturers and suppliers, which makes the company vulnerable to potential supply shortages and problems.
• Risk of failure to comply with post-marketing regulatory requirements.
• Potential misuse or off-label use of products.
• Risk of security breaches, including cybersecurity incidents.
• Potential political, economic and military instability in Israel, where the company's headquarters, members of its management team and its research and development facilities are located.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future and will require substantial additional capital to operate and commercialize its products.

Industry Context

The company operates in the competitive medical device industry, specifically targeting the respiratory care market, which is expected to reach $29.86 billion in 2025. The company aims to offer innovative solutions to address the limitations and complications associated with traditional mechanical ventilation.

Comparison to Industry Standards

• Inspira Technologies faces competition from established medical device companies such as Medtronic, ResMed, and Philips Healthcare, which have greater resources and market presence.
• The INSPIRA ART system aims to offer a less invasive alternative to traditional mechanical ventilators, potentially reducing complications and costs associated with ICU stays.
• The HYLA blood sensor is being developed to provide continuous, real-time monitoring of blood parameters, which could improve patient care and reduce the need for frequent blood draws.
• The INSPIRA ART100 system competes with existing cardiopulmonary bypass systems, offering a compact design and compatibility with various disposable parts.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of losing their investment if the company is unable to secure additional funding.
• Employees may be affected by potential disruptions to operations due to financial instability or military conflicts in Israel.
• Customers (hospitals and medical centers) may benefit from innovative life support technologies, but face uncertainty regarding the company's long-term viability.
• Suppliers and distributors may be impacted by potential supply shortages or disruptions to the company's operations.

Next Steps

• Continue research and development of the INSPIRA ART system and other product candidates.
• Pursue regulatory approvals for the INSPIRA ART system and HYLA blood sensor.
• Establish and expand strategic collaborations with hospitals and medical device companies.
• Commercialize the INSPIRA ART100 system and prepare for potential ramp-up in production.
• Develop and launch single-use disposables for blood oxygenation procedures.
• Complete regulatory submission of the INSPIRA Cardi-ART by early 2026.
• Address Nasdaq non-compliance and regain eligibility for continued listing.

Key Dates